Navigation Links
Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists
Date:5/28/2009

EXTON, Pa., May 28 /PRNewswire/ -- BioTrends Research Group today released its syndicated report TreatmentTrends(R): Psoriasis, the fourth annual survey of U.S. Dermatologists (n=150). The report, based on results of an on-line survey fielded in April, highlights shifting trends in the management of psoriasis and psoriatic arthritis. This comprehensive report covers treatment approaches for mild, moderate, and severe patients with an emphasis on the evolving use of biologic agents.

The vast majority of psoriasis patients across all disease severity categories are prescribed topical agents. The most important attributes for topical agents, according to the respondents, are "Safe when used long term", "Efficacy", and "Covered by insurance plans". Galderma's Vectical, which was approved in February, is the only vitamin D3 ointment indicated for psoriasis and already has a perceived advantage on one of the most important attributes. 61% of the Dermatologists surveyed had prescribed Vectical, but market share is less than 3%. Taclonex and Clobex are the market share leaders for topical agents.

Use of oral agents to treat moderate and severe psoriasis declined for the second year in a row. Use of oral agents is divided primarily between methotrexate and Steifel's (now owned by GSK) Soriatane. Almost half of the surveyed Dermatologists identify methotrexate as the first line oral choice whereas 43% choose Soriatane.

On April 8th, 2009, Genentech and Roche announced the voluntary withdrawal of Raptiva from the U.S. market. Among the Dermatologists surveyed, 41% had patients on Raptiva at the time of the announcement, but only 11% had prescribed the product for a new patient in the past year. While 15% of the patients being treated with Raptiva are expected to be discontinued from biologic therapy, it appears that Enbrel (Amgen/Wyeth) and Humira (Abbott) stand to g
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
2. New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation
3. Radio wave cooling offers new twist on laser cooling
4. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
5. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
6. Microtest Offers Free White Paper: Virus Testing for Biological Products: Partnering With a Contract Lab
7. HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device
8. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
9. Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community
10. New Online Help Desk Offers Safe Lifting Assistance to Healthcare Facilities
11. Woodbridge Offers the Broadest Range of BioFoam(TM) Green Polyurethane Automotive Interior Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Research and Markets  has announced ... Mass Spectrometer Industry Report 2014" report to their ... Mass Spectrometer Industry Report 2014 is a professional and ... isotope ratio mass spectrometer industry. The report ... classifications, applications and industry chain structure. The isotope ratio ...
(Date:8/27/2014)... Palm Beach County, Florida (PRWEB) August 27, 2014 ... & Company Inc. (SCI) is announcing the creation ... board’s priority is to take the SCI’s philosophy ... insuring the company’s research and development actions are ... interpretations. , This new Scientific Advisory Board provides ...
(Date:8/27/2014)... According to the 2013 Raw Material and ... and feel of markets for raw materials and ingredient ... push for more branded, science-backed products.” , Natural products ... growth in the last decade as consumers increasingly demand ... to fit a more ‘wellness’ lifestyle approach. Due ...
(Date:8/27/2014)... August 27, 2014 Budding Biomedical ... University School participated in the Scientific ... Reserve University’s School of Medicine . ... an unparalleled professional experience in the sciences and ... Medicine faculty and students for both academic and ...
Breaking Biology Technology:Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... Sept. 23 S*BIO Pte Ltd today announced ... will support the continued development of S*BIO,s clinical ... reflects the international investment community,s strong interest in ... clinical development and the quality of our various ...
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of results from a randomized Phase 2 trial ... results showed a survival benefit with the investigational ... cancer. The median overall survival for patients who ...
Cached Biology Technology:S*BIO Announces US$5 Million Investment by Mitsui Ventures 2S*BIO Announces US$5 Million Investment by Mitsui Ventures 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 2OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 3OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 4OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 5
(Date:8/27/2014)... -- When we want to listen carefully to someone, ... second thing we do is stop moving altogether. This ... generated by our own movements. , This interplay between ... the brain. Indeed, indirect evidence has long suggested that ... the auditory cortex, which gives rise to our conscious ...
(Date:8/27/2014)... Aug. 27, 2014 /PRNewswire-iReach/ -- The IEEE Engineering in ... th Annual International Conference (EMBC,14), this year being ... Chicago, Illinois , from Tuesday, August ... leaders, students, and industry professionals in science, medicine, and ... http://photos.prnewswire.com/prnh/20140827/140333 This year,s conference ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... Do you want that in a pill or a shot? ... choice. The problem with administering many medications orally is that ... site in the gastrointestinal tract where the medicine can be ... by Brown University researchers could solve the problem by safely ...
... with common blood pressure medications may cause hypotension ... older patients, requiring hospitalization, according to a study ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100702.pdf ... are among the most widely prescribed antibiotics, with ...
... Stanford University School of Medicine, in collaboration with BioParadox, ... plasma as a promising biologic treatment for myocardial infarction ... online in Cardiovascular Revascularization Medicine and will ... Therapy for Cardiovascular Disease at Columbia University Medical Center, ...
Cached Biology News:Magnetically controlled pill could boost body's absorption of drugs 2RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: